Standard
The risk of COVID-19 infection in patients with atopic dermatitis : A retrospective cohort study. / Wu, Jashin J.; Martin, Amylee; Liu, Jeffrey; Thatiparthi, Akshitha; Ge, Shaokui; Egeberg, Alexander; Thyssen, Jacob P.
In:
Journal of the American Academy of Dermatology, Vol. 86, No. 1, 01.2022, p. 243-245.
Research output: Contribution to journal › Comment/debate › Research › peer-review
Harvard
Wu, JJ, Martin, A, Liu, J, Thatiparthi, A, Ge, S
, Egeberg, A & Thyssen, JP 2022, '
The risk of COVID-19 infection in patients with atopic dermatitis: A retrospective cohort study',
Journal of the American Academy of Dermatology, vol. 86, no. 1, pp. 243-245.
https://doi.org/10.1016/j.jaad.2021.09.061APA
Wu, J. J., Martin, A., Liu, J., Thatiparthi, A., Ge, S.
, Egeberg, A., & Thyssen, J. P. (2022).
The risk of COVID-19 infection in patients with atopic dermatitis: A retrospective cohort study.
Journal of the American Academy of Dermatology,
86(1), 243-245.
https://doi.org/10.1016/j.jaad.2021.09.061Vancouver
Wu JJ, Martin A, Liu J, Thatiparthi A, Ge S
, Egeberg A et al.
The risk of COVID-19 infection in patients with atopic dermatitis: A retrospective cohort study.
Journal of the American Academy of Dermatology. 2022 Jan;86(1):243-245.
https://doi.org/10.1016/j.jaad.2021.09.061Author
Wu, Jashin J. ; Martin, Amylee ; Liu, Jeffrey ; Thatiparthi, Akshitha ; Ge, Shaokui ; Egeberg, Alexander ; Thyssen, Jacob P. / The risk of COVID-19 infection in patients with atopic dermatitis : A retrospective cohort study. In: Journal of the American Academy of Dermatology. 2022 ; Vol. 86, No. 1. pp. 243-245.
Bibtex
@article{d2133d679b1f4ff0b2a395f0d74ec41a,
title = "The risk of COVID-19 infection in patients with atopic dermatitis: A retrospective cohort study",
keywords = "atopic dermatitis, COVID-19, dupilumab, epidemiology, infection",
author = "Wu, {Jashin J.} and Amylee Martin and Jeffrey Liu and Akshitha Thatiparthi and Shaokui Ge and Alexander Egeberg and Thyssen, {Jacob P.}",
note = "Funding Information: Dr Wu is or has been an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Aristea Therapeutics, Boehringer Ingelheim, Bristol–Myers Squibb, Dermavant, Dr Reddy's Laboratories, Eli Lilly, Galderma, Janssen, LEO Pharma, Mindera, Novartis, Regeneron, Sanofi Genzyme, Solius, Sun Pharmaceutical, UCB, Valeant Pharmaceuticals North America LLC, and Zerigo Health. Dr Egeberg has received research funding from Pfizer , Eli Lilly , Novartis , Bristol-Myers Squibb , AbbVie , Janssen Pharmaceuticals , the Danish National Psoriasis Foundation , the Simon Spies Foundation , and the Aage Bang's Foundation , and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Gal{\'a}pagos NV, Sun Pharmaceuticals, Samsung Bioepis Co, Ltd, Pfizer, Eli Lilly, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol–Myers Squibb, and Janssen Pharmaceuticals. Dr Thyssen has been an advisor, speaker, or investigator for AbbVie, LEO Pharma, Regeneron, Pfizer, Sanofi Genzyme, Almirall, and Eli Lilly. Dr Ge and Authors Martin, Liu, and Thatiparthi have no conflicts of interest to declare. Funding Information: Dr Wu is or has been an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Aristea Therapeutics, Boehringer Ingelheim, Bristol?Myers Squibb, Dermavant, Dr Reddy's Laboratories, Eli Lilly, Galderma, Janssen, LEO Pharma, Mindera, Novartis, Regeneron, Sanofi Genzyme, Solius, Sun Pharmaceutical, UCB, Valeant Pharmaceuticals North America LLC, and Zerigo Health. Dr Egeberg has received research funding from Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Aage Bang's Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Gal?pagos NV, Sun Pharmaceuticals, Samsung Bioepis Co, Ltd, Pfizer, Eli Lilly, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol?Myers Squibb, and Janssen Pharmaceuticals. Dr Thyssen has been an advisor, speaker, or investigator for AbbVie, LEO Pharma, Regeneron, Pfizer, Sanofi Genzyme, Almirall, and Eli Lilly. Dr Ge and Authors Martin, Liu, and Thatiparthi have no conflicts of interest to declare.",
year = "2022",
month = jan,
doi = "10.1016/j.jaad.2021.09.061",
language = "English",
volume = "86",
pages = "243--245",
journal = "American Academy of Dermatology. Journal",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "1",
}
RIS
TY - JOUR
T1 - The risk of COVID-19 infection in patients with atopic dermatitis
T2 - A retrospective cohort study
AU - Wu, Jashin J.
AU - Martin, Amylee
AU - Liu, Jeffrey
AU - Thatiparthi, Akshitha
AU - Ge, Shaokui
AU - Egeberg, Alexander
AU - Thyssen, Jacob P.
N1 - Funding Information:
Dr Wu is or has been an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Aristea Therapeutics, Boehringer Ingelheim, Bristol–Myers Squibb, Dermavant, Dr Reddy's Laboratories, Eli Lilly, Galderma, Janssen, LEO Pharma, Mindera, Novartis, Regeneron, Sanofi Genzyme, Solius, Sun Pharmaceutical, UCB, Valeant Pharmaceuticals North America LLC, and Zerigo Health. Dr Egeberg has received research funding from Pfizer , Eli Lilly , Novartis , Bristol-Myers Squibb , AbbVie , Janssen Pharmaceuticals , the Danish National Psoriasis Foundation , the Simon Spies Foundation , and the Aage Bang's Foundation , and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co, Ltd, Pfizer, Eli Lilly, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol–Myers Squibb, and Janssen Pharmaceuticals. Dr Thyssen has been an advisor, speaker, or investigator for AbbVie, LEO Pharma, Regeneron, Pfizer, Sanofi Genzyme, Almirall, and Eli Lilly. Dr Ge and Authors Martin, Liu, and Thatiparthi have no conflicts of interest to declare.
Funding Information:
Dr Wu is or has been an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Aristea Therapeutics, Boehringer Ingelheim, Bristol?Myers Squibb, Dermavant, Dr Reddy's Laboratories, Eli Lilly, Galderma, Janssen, LEO Pharma, Mindera, Novartis, Regeneron, Sanofi Genzyme, Solius, Sun Pharmaceutical, UCB, Valeant Pharmaceuticals North America LLC, and Zerigo Health. Dr Egeberg has received research funding from Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Aage Bang's Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Gal?pagos NV, Sun Pharmaceuticals, Samsung Bioepis Co, Ltd, Pfizer, Eli Lilly, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol?Myers Squibb, and Janssen Pharmaceuticals. Dr Thyssen has been an advisor, speaker, or investigator for AbbVie, LEO Pharma, Regeneron, Pfizer, Sanofi Genzyme, Almirall, and Eli Lilly. Dr Ge and Authors Martin, Liu, and Thatiparthi have no conflicts of interest to declare.
PY - 2022/1
Y1 - 2022/1
KW - atopic dermatitis
KW - COVID-19
KW - dupilumab
KW - epidemiology
KW - infection
U2 - 10.1016/j.jaad.2021.09.061
DO - 10.1016/j.jaad.2021.09.061
M3 - Comment/debate
C2 - 34626733
AN - SCOPUS:85118257416
VL - 86
SP - 243
EP - 245
JO - American Academy of Dermatology. Journal
JF - American Academy of Dermatology. Journal
SN - 0190-9622
IS - 1
ER -
